HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in Schizophrenia

Journal of Clinical Psychopharmacology

Volumn 35, Issue 3, 2015, Pages 220-227

  Takekita, Yoshiteru ^a,b   Fabbri, Chiara ^a   Kato, Masaki ^b   Nonen, Shinpei ^c   Sakai, Shiho ^b   Sunada, Naotaka ^b   Koshikawa, Yosuke ^b   Wakeno, Masataka ^b   Okugawa, Gaku ^b   Kinoshita, Toshihiko ^b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

5 HT1A receptor partial agonism; antipsychotics; efficacy; HTR1A; schizophrenia

Indexed keywords

ARIPIPRAZOLE; PEROSPIRONE; SEROTONIN 1A RECEPTOR; HTR1A PROTEIN, HUMAN; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; SEROTONIN 1 AGONIST; THIAZOLE DERIVATIVE;

ADULT; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOTYPE; HAPLOTYPE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; FEMALE; HAPLOTYPES; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1A; SCHIZOPHRENIA; SEROTONIN 5-HT1 RECEPTOR AGONISTS; THIAZOLES; TREATMENT OUTCOME;

EID: 84929149211     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000304     Document Type: Article

References (66)

1. Kapur S, Seeman P,. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001; 158: 360-369.
2. Jordan S, Koprivica V, Chen R, The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002; 441: 137-140.
3. Newman-Tancredi A,. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. C urr Opin Investig Drugs. 2010; 11: 802-812.
4. Barnes NM, Sharp T,. A review of central 5-HT receptors and their function. Neuropharmacology. 1999; 38: 1083-1152.
5. Aznar S, Qian Z, Shah R, The 5-HT1A serotonin receptor is located on calbindin-and parvalbumin-containing neurons in the rat brain. Brain Res. 2003; 959: 58-67.
6. Varnas K, Halldin C, Hall H,. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 2004; 22: 246-260.
7. Hashimoto T, Nishino N, Nakai H, Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991; 48: 355-363.
8. Sumiyoshi T, Stockmeier CA, Overholser JC, Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996; 708: 209-214.
9. Burnet PW, Eastwood SL, Harrison PJ,. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 1996; 15: 442-455.
10. Tauscher J, Kapur S, Verhoeff NP, Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry. 2002; 59: 514-520.
11. Hollister LE,. New psychotherapeutic drugs. J Clin Psychopharmacol. 1994; 14: 50-63.
12. Newman-Tancredi A, Kleven MS,. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011; 216: 451-473.
13. Sumiyoshi T, Matsui M, Yamashita I, Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol. 2000; 20: 386-388.
14. Sumiyoshi T, Matsui M, Nohara S, Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001; 158: 1722-1725.
15. Sirota P, Epstein B, Benatov R, An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol. 2001; 21: 454-455.
16. Ghaleiha A, Noorbala AA, Farnaghi F, A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J Clin Psychopharmacol. 2010; 30: 678-682.
17. Arranz MJ, De Leon J,. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007; 12: 707-747.
18. The Nucleotide database [database online] Bethesda, MD 1982. September 1, 2014. Available at: http://www.ncbi.nlm.nih.gov/nucleotide/. Accessed September 16, 2014.
19. Wu S, Comings DE,. A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet. 1999; 9: 105-106.
20. Lemonde S, Turecki G, Bakish D, Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003; 23: 8788-8799.
21. Albert PR, Lemonde S,. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist. 2004; 10: 575-593.
22. Fabbri C, Di Girolamo G, Serretti A,. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet. 2013; 162B: 487-520.
23. Odagaki Y, Toyoshima R,. 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes. Clin Exp Pharmacol Physiol. 2007; 34: 462-466.
24. Murasaki M, Nishikawa H, Ishibashi T,. Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin. Japanese Clinical Psychopharmacology. 2008; 11: 845-854.
25. Fagiolini A, Canas F, Gallhofer B, Strategies for successful clinical management of schizophrenia with ziprasidone. Expert Opin Pharmacother. 2010; 11: 2199-2220.
26. Lerond J, Lothe A, Ryvlin P, Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. J Clin Psychopharmacol. 2013; 33: 84-89.
27. Ichikawa J, Ishii H, Bonaccorso S, 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001; 76: 1521-1531.
28. Diaz-Mataix L, Scorza MC, Bortolozzi A, Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci. 2005; 25: 10831-10843.
29. Bortolozzi A, Masana M, Diaz-Mataix L, Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. Int J Neuropsychopharmacol. 2010; 13: 1299-1314.
30. Takekita Y, Kato M, Wakeno M, A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 110-114.
31. Inagaki A, Inada T,. Dose equivalence of psychotropic drugs. Part X VII: dose equivalence of novel antipsychotics: aripiprazole. Jpn J Clin Psychopharmacol. 2006; 9: 249-258.
32. Lindenmayer JP, Grochowski S, Hyman RB,. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995; 14: 229-234.
33. Citrome L, Meng X, Hochfeld M,. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res. 2011; 131: 75-81.
34. Reynolds GP, Arranz B, Templeman LA, Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry. 2006; 163: 1826-1829.
35. Wang L, Fang C, Zhang A, The-1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol. 2008; 22: 904-909.
36. Mossner R, Schuhmacher A, Kuhn KU, Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics. 2009; 19: 91-94.
37. Sumiyoshi T, Tsunoda M, Higuchi Y, Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv Ther. 2010; 27: 307-313.
38. Crisafulli C, Chiesa A, Han C, Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2012; 262: 199-205.
39. Chiesa A, Lia L, Han C, Investigation of epistasis between DAOA and 5HTR1A variants on clinical outcomes in patients with schizophrenia. Genet Test Mol Biomarkers. 2013; 17: 504-507.
40. The International HapMap Project [database online] Bethesda, MD 2003. April 2, 2009. Available at: http://hapmap.ncbi.nlm.nih.gov/index.html.en. Accessed September 16, 2014.
41. Haploview [computer program]. Version 4.2, Cambridge, MA: Daly Lab at the Broad Institute; 2008.
42. R: A Language and Environment for Statistical Computing [computer program]. Version 3.1.0, Vienna, Austria: R Development Core Team; 2014.
43. G∗Power [computer program]. Version 3.1.7, Düsseldorf, Germany: Heinrich-Heine-Universität; 2013.
44. Cohen J,. A power primer. Psychol Bull. 1992; 112: 155-159.
45. Cohen J,. Statistical power analysis for the behavioral sciences. 2nd ed. Mahwah, New Jersey: Lawrence Erlbaum Associates, Inc., 1988.
46. Sumiyoshi T, Matsui M, Yamashita I, The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry. 2001; 49: 861-868.
47. Silver H,. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 2004; 5: 2053-2058.
48. Boulay D, Depoortere R, Louis C, SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology. 2004; 46: 1121-1129.
49. Bruins Slot LA, Kleven MS, Newman-Tancredi A,. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology. 2005; 49: 996-1006.
50. Sumiyoshi T, Park S, Jayathilake K, Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007; 95: 158-168.
51. Madjid N, Tottie EE, Luttgen M, 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther. 2006; 316: 581-591.
52. Horiguchi M, Meltzer HY,. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl). 2012; 221: 205-215.
53. Kato M, Fukuda T, Wakeno M, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B: 115-123.
54. Villafuerte SM, Vallabhaneni K, Sliwerska E, SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet. 2009; 19: 281-291.
55. Zhao X, Jin Q, Wu L, Sertraline (Zoloft) response in major depressive disorder is not associated with three 5-HT1A receptor gene polymorphisms (rs6295, rs10042486, or rs1364043) in Chinese-Han patients. Psychiatr Genet. 2012; 22: 261-262.
56. Lin PI, Vance JM, Pericak-Vance MA, No gene is an island: the flip-flop phenomenon. Am J Hum Genet. 2007; 80: 531-538.
57. Di Matteo V, Di Giovanni G, Di Mascio M, Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res. 2000; 865: 85-90.
58. Celada P, Puig MV, Artigas F,. Serotonin modulation of cortical neurons and networks. Front Integr Neurosci. 2013; 7: 25.
59. Huang M, Panos JJ, Kwon S, Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem. 2014; 128: 938-949.
60. Jacobsen KX, Vanderluit JL, Slack RS, HES1 regulates 5-HT1A receptor gene transcription at a functional polymorphism: essential role in developmental expression. Mol Cell Neurosci. 2008; 38: 349-358.
61. Albert PR,. Transcriptional regulation of the 5-HT1A receptor: implications for mental illness. Philos Trans R Soc Lond B Biol Sci. 2012; 367: 2402-2415.
62. Czesak M, Le Francois B, Millar AM, Increased serotonin-1A (5-HT1A) autoreceptor expression and reduced raphe serotonin levels in deformed epidermal autoregulatory factor-1 (Deaf-1) gene knock-out mice. J Biol Chem. 2012; 287: 6615-6627.
63. Czesak M, Lemonde S, Peterson EA, Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. J Neurosci. 2006; 26: 1864-1871.
64. Varrault A, Journot L, Audigier Y, Transfection of human 5-hydroxytryptamine1A receptors in NIH-3T3 fibroblasts: effects of increasing receptor density on the coupling of 5-hydroxytryptamine1A receptors to adenylyl cyclase. Mol Pharmacol. 1992; 41: 999-1007.
65. Casey DE, Carson WH, Saha AR, Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166: 391-399.
66. Pae CU, Serretti A, Chiesa A, Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol. 2009; 19: 562-570.